





To the Editor: The year 2009 was 
the 100th anniversary of Carlos Cha-
gas’s discovery of the disease caused 
by the parasite Trypanosoma cruzi, 
now known as Chagas disease. Spread 
by infected bugs called triatomines, the 
disease is endemic throughout much of 
Mexico and Central and South Ameri-
ca. An estimated 8–11 million persons 
in Latin America have the disease (1). 
T. cruzi infection causes more public 
health problems with long-term con-
sequences in Latin America than any 
other parasitic disease (2).
Although earlier estimates sug-
gested that 100,000 infected persons 
may live in the United States (3), recent 
data suggest that ≈300,000 persons are 
infected (4). Most of these persons are 
unaware that they are infected. Anti-
parasitic drugs to treat Chagas disease 
have not been approved by the US 
Food and Drug Administration and 
are only available in the United States 
through the Centers for Disease Con-
trol and Prevention (CDC) for use un-
der investigational protocols for com-
passionate treatment.
Screening of the US blood supply 
for Chagas disease began in early 2007; 
more than 500 donors with T. cruzi in-
fection were identiﬁ  ed within the ﬁ  rst 
18 months (5). However, to date, only 
≈11% of T. cruzi–positive donors (or 
their physicians) have contacted CDC 
for treatment consultations (CDC, un-
pub. data). One possible explanation is 
the limited awareness of Chagas dis-
ease in the United States among health 
professionals, the general public, and 
even among Mexican-born Americans 
(K.K. Stimpert and S.P. Montgomery, 
unpub. data).
To assess healthcare provider 
awareness of Chagas disease, a study 
was conducted by MedscapeCME 
(www.medscape.com) with technical 
support from CDC. MedscapeCME, a 
leading provider of online clinical and 
medical information and continuing 
medical education (CME) for physi-
cians and other healthcare profession-
als, carried out a knowledge, attitudes, 
and practices (KAP) assessment of 
physician members of its website. Re-
searchers anticipated that the results of 
the study would inform larger formal 
studies among healthcare providers 
in geographic areas where population 
demographics and blood donor screen-
ing results suggest that persons are at 
risk for Chagas disease.
The KAP study was based on 
ﬁ  ve 10-question surveys, which were 
posted on the MedscapeCME website. 
Each survey was tailored for a speciﬁ  c 
specialty: primary care, infectious 
disease, cardiology, obstetrics/gyne-
cology, and transplantation medicine; 
they were designed to measure basic 
knowledge of Chagas disease epide-
miology and consideration of Chagas 
disease risk among these physicians.
MedscapeCME members were 
given the option of participating in 
the surveys when they logged onto 
each specialty site. MedscapeCME 
membership requirements include 
online registration, which is validated 
by conﬁ  rming American Medical As-
sociation membership. Each member 
could complete the survey only once. 
All surveys were launched on Decem-
ber 11, 2008, but discontinued at dif-
ferent times (median 39 days).
Although familiarity with Chagas 
disease varied by specialty, the results 
suggested that a general lack of aware-
ness was common across all groups 
(Table). This awareness deﬁ  cit  was 
most pronounced in obstetricians and 
gynecologists and least pronounced in 
infectious disease physicians (Table). 
The 7 responses to questions outlined 
in the Table may be placed in 3 cat-
egories: 1) general awareness of Cha-
gas disease (questions 1 and 3), 2) 
conﬁ  dence in Chagas disease knowl-
edge and consideration of risk (ques-
tions 2 and 5), and 3) clinical aspects 
of Chagas disease (questions 4, 6, and 
7). Across all 3 domains, obstetricians 
and gynecologists reported low knowl-
edge of Chagas disease and a low lev-
el of conﬁ  dence in their knowledge. 
Infectious disease physicians had the 
highest levels of knowledge and con-
ﬁ  dence across all domains, except for 
responses to question 1 (Table).
Survey results suggest substan-
tial knowledge deﬁ  cits among physi-
cians, especially among obstetricians 
and gynecologists. The apparent lack 
of knowledge in the obstetrics and 
gynecology community is of particu-
lar concern because Chagas disease 
can be transmitted congenitally (6). 
Because Chagas disease may also be 
transmitted by organ transplantation, 
the proportion of respondents from 
this specialty who indicated they nev-
er consider risk for Chagas disease in 
their patients (39%) is also notable. In 
fact, many physicians surveyed never 
consider the risk for Chagas disease in 
their patient population (29%–60%) 
and are not at all conﬁ  dent that their 
knowledge of Chagas disease is cur-
rent (27%–68%).
The study has some limitations. 
The conclusions are drawn from a 
study in which convenience samples 
from selected populations were used 
and are thus not generalizable to larg-
er healthcare provider populations in 
the United States. The high participa-
tion rate of transplant surgeons may 
reﬂ  ect  a  ﬂ   uctuation in membership 
numbers. In addition, transplant sur-
geons may have an increased interest 
in Chagas disease because of recent 
instances of transplant-associated 
transmission (7,8).
These preliminary data suggest a 
substantial knowledge deﬁ  cit regard-
ing Chagas disease among healthcare 
providers, which could have a nega-
tive effect on patient health if Chagas 
disease is not recognized and appro-
priately treated. CDC plans to conduct 
larger scale KAP surveys of physicians 
in areas where blood donor screening 
results suggest relatively high preva-
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lence in the underlying communities. 
For example, T. cruzi infection preva-
lence in blood donors in Florida and 
California was reported to be 1/3,700 
and 1/8,300, respectively (5). Future 
studies will help document why Cha-
gas disease is underrecognized in the 
United States and further demonstrate 
the need for educating healthcare pro-
viders about this disease.
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Table. Reponses to MedscapeCME knowledge, attitudes, and practices survey questions reflecting lack of knowledge about Chagas 
disease, by specialty* 
Response
No. (%) respondents† 
Cardiology, 
n = 280  
Infectious
disease, n = 167 
OB/GYN, 
n = 292 
Primary care, 
n = 278 
Transplantation,
n = 125 
Never heard of Chagas disease‡  63 (23)  31 (19)  138 (47)  38 (14)  35 (25) 
Not at all confident of Chagas disease knowledge 
being up to date§ 
87 (44)  31 (27)  86 (68)  101 (47)  41 (48) 
Did not know parasite causes Chagas disease¶  21 (16)  6 (5)  42 (33)  35 (16)  15 (17) 
Did not know cardiac and/or gastrointestinal disease 
are manifestations of Chagas disease# 
15 (8)  10 (9)  38 (30)  24 (11)  11 (13) 
Never considers risk for Chagas disease in patients**  51 (34)  30 (29)  66 (60)  83 (43)  29 (39) 
Did not know in what percentage of patients with 
chronic infection clinical disease develops†† 
66 (37)  30 (28)  60 (56)  93 (48)  35 (47) 
Did not know Chagas disease symptoms‡‡  41 (23)  15 (14)  53 (48)  52 (27)  22 (29) 
*OB/GYN, obstetrics/gynecology. 
†Percentages are calculated based on number of respondents per question, by specialty. 
‡Question 1: Have you heard of Chagas disease? Answer choices: yes, no. 
§Question 2: How confident are you that your Chagas disease knowledge is up to date? Answer choices: very confident, confident, somewhat confident, 
not at all confident. 
¶Question 3: Chagas disease is caused by a ___? Answer choices: bacterium, virus, parasite, fungus, I don’t know. 
#Question 4: People with chronic Chagas disease may have (check all that apply)? Answer choices: cardiac conduction abnormalities, cardiomyopathy, 
megacolon, co-clinical manifestations, I don’t know. 
**Question 5: How often do you consider the risk for Chagas disease in your patient population? Answer choices: never, rarely, sometimes, frequently, 
always. 
††Question 6: Approximately what percentage of patients with chronic Chagas infection eventually develop clinical disease? Answer choices: <20%, 
21%–40%, >40%, I don’t know. 
‡‡Question 7: Chagas disease symptoms are? Answer choices: Acute for several weeks then immediately symptomatic, Acute for several weeks 
asymptomatic for years to decades then sometimes symptomatic, There are no symptoms of Chagas disease, I don’t know. 